1. 1265PPhase Ib/II study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who had progressive disease on or after prior anti-PD-1 therapy. (23rd October 2018) Authors: Ribas, A; Mehmi, I; Medina, T; Lao, C; Kummar, S; Amin, A; Deva, S; Salama, A K; Tueting, T; Milhem, M; Hoimes, C J; Daniels, G; Shaheen, M; Jang, S; Barve, M; Powell, A; Chandra, S; Schmidt, E V; Janssen, R; Long, G V Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Adalimumab-induced bronchospasm: not a class effect. Issue 5 (28th April 2008) Authors: Janssen, R; Krivokuca, I; Kruize, A A; Koenderman, L; Lammers, J-W J Journal: Thorax Issue: Volume 63:Issue 5(2008) Page Start: 472 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. TIMP-3 promoter gene polymorphisms in BFL. Issue 11 (1st November 2005) Authors: Janssen, R; Kruit, A; Grutters, J C; Ruven, H J T; van Moorsel, C M H; van den Bosch, J M M Journal: Thorax Issue: Volume 60:Issue 11(2005) Page Start: 974 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗